Therapeutic Antibody for CMV
Description: Project Narrative. This SBIR CRP project will advance the development of TRL345, a native human therapeutic monoclonal antibody against a highly conserved site on Human Cytomegalovirus (HCMV) gB protein. The antibody provides broad spectrum protection against clinical HCMV strains which are a leading cause of disease in transplant patients and a key contributor to birth defects when transmitted from mother to developing fetus. The project will supplement other funding to accelerate initiation of clinical trials by supporting the acquisition of services in manufacturing and regulatory consulting.
Funder: National Institutes of Health
Amount: $999,000
Funding type: grant
Funder scheme: SB1
Start date: 2012-08-01
End date: 2020-04-30
Investigator: LAWRENCE MICHAEL KAUVAR
Institution: TRELLIS BIOSCIENCE, INC.
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 1
Funder award ID: 2sb1ai102396-06
OpenAlex ID: G190886366